Chinmay Jani, Clinical Fellow of Hematology and Oncology at the University of Miami, shared a post on X:
“Target the driver, not just the disease!
RET+? Selpercatinib > chemo+ICI in front line! (PFS 24.8 mo, ORR 84%)
ALK+? Lorlatinib shows unmatched CNS activity
Best fusion detection? RNA + DNA combo!
Great panel discussion chaired by Millie Das.”
More posts featuring TexasLung25.
